Incidental venous thromboembolic events in cancer patients: what we know in 2016.

Thromb Res

Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases, University of California-Keck School of Medicine, Los Angeles, CA, USA.

Published: April 2016

Cancer patients are at high risk of venous thromboembolism (VTE). Previous reports on the epidemiology and incident of thrombotic complications in cancer patients are based upon documented symptomatic events. However, the frequent use of contrast enhanced computerized tomography for cancer staging has documented a high incidence of unsuspected venous thrombosis (DVT), pulmonary embolism (PE) and abdominal visceral thrombosis in cancer patients. Recent studies focusing on the findings of incidental PE when compared to symptomatic PE find no significant difference in pulmonary distribution of clots, incidence of VTE recurrence or survival in these patients. Based upon these studies, current guidelines recommend treatment for incidental PE as recommended for symptomatic PE.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129141PMC
http://dx.doi.org/10.1016/S0049-3848(16)30093-7DOI Listing

Publication Analysis

Top Keywords

cancer patients
16
patients based
8
cancer
5
patients
5
incidental venous
4
venous thromboembolic
4
thromboembolic events
4
events cancer
4
patients 2016
4
2016 cancer
4

Similar Publications

Erlotinib-induced Perioral Lesions Resembling Scleroderma.

Acta Dermatovenerol Croat

November 2024

Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.

View Article and Find Full Text PDF

Objective: To examine the role and diagnostic potential of miR-421 in prostate cancer (PCa).

Methods: Expression data and clinical information for miR-421 were obtained from the TCGA and Genotype-Tissue Expression (GTEx) databases. Experimental validation was performed at the cellular, blood, and tissue levels to confirm miR-421 expression and its association with clinicopathological features.

View Article and Find Full Text PDF

Cardamonin anticancer effects through the modulation of the tumor immune microenvironment in triple-negative breast cancer cells.

Am J Cancer Res

December 2024

Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University Tallahassee, FL 32307, The United States.

The tumor immune microenvironment (TIME) plays a critical role in cancer development and response to immunotherapy. Immune checkpoint inhibitors aim to reverse the immunosuppressive effects of the TIME, but their success has been limited. Immunotherapy directed at PD-1/PD-L1 has been widely employed, yielding positive results.

View Article and Find Full Text PDF

Background: Ultra-low rectal endoscopic submucosal dissection (ESD) presents technical challenges due to anatomical features. The objective of this research was to determine the risk factors linked to unsuccessful curative resections and to create a nomogram predictive model to assess the likelihood of encountering technical challenges.

Methods: Patients with ultra-low rectal tumors received ESD form June 2017 to December 2022 were retrospectively enrolled.

View Article and Find Full Text PDF

N staging systems are paramount clinical features for colorectal cancer (CRC). In N1 stage (N1) CRC, patients present with a limited number of metastatic lymph nodes, yet their prognoses vary widely. The tumor invasion proportion of lymph nodes (TIPLN) has gained attention, but its prognostic value in N1 CRC remains unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!